GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

"A number of serious bacterial diseases still lack vaccines while antibiotic resistance is growing and the costs for vaccines development is increasing," said Philippe Dro, CEO of GlycoVaxyn. "Setbacks in vaccine development, most recently with Staphylococcus aureus, highlight the challenges facing the vaccine industry and public health professionals.  Our science day provides a forum for industry, regulatory and academic thought leaders to address today's challenges and discuss solutions and recent developments in vaccines. This is our second annual science day, following a very successful event last year."

GlycoVaxyn's Second Annual Science Day will include presentations from prominent speakers from the vaccine industry from both sides of the Atlantic.  Topics will include recent developments in glycoconjugate technology and the current state-of-the-art of meningococcal and staphylococcal vaccines. A copy of the agenda can be found at Second Annual Science Day.